BioCentury | Mar 1, 2019
Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

...acromegaly, Nutropin AQ for growth failure, Increlex mecasermin for growth delay and cancer therapy Decapeptyl triptorelin pamoate...
BioCentury | Feb 25, 2019
Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

...acromegaly, Nutropin AQ for growth failure, Increlex mecasermin for growth delay and cancer therapy Decapeptyl triptorelin pamoate...
BioCentury | Jul 27, 2017
Clinical News

FDA approves Triptodur for central precocious puberty

...LLC , Atlanta, Ga. Debiopharm Group , Lausanne, Switzerland Product: Triptodur triptorelin Business: Endocrine/Metabolic Julian Zhu Debio 8206 SC Decapeptyl Triptorelin triptorelin pamoate Arbor...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...ovarian cancer has only three: the VEGF inhibitor Avastin bevacizumab; the GnRH/LHRH receptor agonist Decapeptyl triptorelin pamoate...
BioCentury | Mar 22, 2017
Clinical News

Decapeptyl regulatory update

...The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a label expansion for Decapeptyl triptorelin pamoate...
...of recurrence or who are confirmed premenopausal after completion of chemotherapy. The controlled-release formulation of triptorelin pamoate...
...and endometriosis. Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Decapeptyl triptorelin pamoate (Trelstar) (Debio 8206) Business: Cancer Julian Zhu Debio 8206 Decapeptyl Trelstar triptorelin pamoate Ipsen...
BioCentury | Nov 16, 2015
Company News

Primm Pharma, Xbrane deal

...following approval in Italy. Xbrane said the product, which is a slow-release formulation of Decapeptyl triptorelin pamoate...
BioCentury | Jul 20, 2015
Clinical News

Triptorelin pamoate: Phase III data

...patients with CPP showed that 2 intramuscular injections of a 6-month formulation of 22.5 mg triptorelin pamoate...
...of the product as Trelstar to treat advanced prostate cancer. Ipsen, which has rights to triptorelin pamoate...
...Switzerland Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Actavis plc , Dublin, Ireland Product: Triptorelin pamoate ( Debio 8206...
BioCentury | Dec 22, 2014
Company News

Actavis, Debiopharm sales and marketing update

...Specialty Pharmaceuticals Co. subsidiary and Debiopharm launched a six-month dosing option of 22.5 mg Trelstar triptorelin pamoate...
...U.S. and Canadian rights to the product from Debiopharm. Trelstar is a controlled-release formulation of triptorelin pamoate...
BioCentury | Dec 8, 2014
Clinical News

Decapeptyl triptorelin pamoate: Additional Phase III data

...locally advanced or metastatic prostate cancer showed that a 3-month formulation of 11.25 mg subcutaneous Decapeptyl...
...of the product as Trelstar to treat advanced prostate cancer. Ipsen, which has rights to triptorelin pamoate...
...Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Actavis plc (NYSE:ACT), Dublin, Ireland Product: Decapeptyl triptorelin pamoate ( Debio 8206...
BioCentury | Jun 9, 2014
Company News

Debiopharm, Orient EuroPharma Co. Ltd. deal

...agonist - is also approved as Trelstar in the U.S. for prostate cancer and as Decapeptyl...
Items per page:
1 - 10 of 55